Abstract
Background: Neurokinin-1 receptor antagonists are playing a major advance in Chemotherapy-Induced Nausea and Vomiting (CINV) as powerful prophylactic agents. Therefore, it is significant to find the association between risk factors of patients and CINV so as to adjust the anti-emetic regimens.
Objective: To evaluate the role of Neurokinin-1 Receptor (NK-1R) antagonist in preventing chemotherapy-induced vomiting in the acute and delayed phases following the first cycle of treatment.
Methods: 145 adult patients with various cancers were recruited in Shanghai Changhai Hospital between September 2017 to November 2017, receiving dual or triple antiemetics.
Results: NK-1R antagonist combined with dexamethasone, 5-HT3R antagonist could effectively control delayed- vomiting in patients after Cycle 1 chemotherapy treatment (4.1% vs. 15.6%, P = 0.041<; 0.05). This study also showed that a history of motion sickness was a predictor of chemotherapy-induced vomiting (CINV) (P = 0.023 <; 0.05). In delayed phase a low consumption of alcohol and history of CIV for males were also significantly associated with CINV (P = 0.036 <; 0.05 and P = 0.002 <; 0.05 respectively).
Conclusion: In this study, we found that triple anti-emetic regimen with NK-1R antagonist could effectively prevent the delayed-vomiting than dual agents. Moreover, some risk factors were observed to be associated with CINV in the delayed phase.
Keywords: Chemotherapy, adverse effect, nausea, vomiting, antiemetic, neurokinin-1 receptor.
Anti-Cancer Agents in Medicinal Chemistry
Title:Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study
Volume: 21 Issue: 16
Author(s): Jing Xu, Shuhui Tang, Jie Li, Wei Wang, Meihong Wu and Xianbao Zhan*
Affiliation:
- Department of Oncology, Changhai Hospital, The Naval Military Medical University, Shanghai,China
Keywords: Chemotherapy, adverse effect, nausea, vomiting, antiemetic, neurokinin-1 receptor.
Abstract:
Background: Neurokinin-1 receptor antagonists are playing a major advance in Chemotherapy-Induced Nausea and Vomiting (CINV) as powerful prophylactic agents. Therefore, it is significant to find the association between risk factors of patients and CINV so as to adjust the anti-emetic regimens.
Objective: To evaluate the role of Neurokinin-1 Receptor (NK-1R) antagonist in preventing chemotherapy-induced vomiting in the acute and delayed phases following the first cycle of treatment.
Methods: 145 adult patients with various cancers were recruited in Shanghai Changhai Hospital between September 2017 to November 2017, receiving dual or triple antiemetics.
Results: NK-1R antagonist combined with dexamethasone, 5-HT3R antagonist could effectively control delayed- vomiting in patients after Cycle 1 chemotherapy treatment (4.1% vs. 15.6%, P = 0.041<; 0.05). This study also showed that a history of motion sickness was a predictor of chemotherapy-induced vomiting (CINV) (P = 0.023 <; 0.05). In delayed phase a low consumption of alcohol and history of CIV for males were also significantly associated with CINV (P = 0.036 <; 0.05 and P = 0.002 <; 0.05 respectively).
Conclusion: In this study, we found that triple anti-emetic regimen with NK-1R antagonist could effectively prevent the delayed-vomiting than dual agents. Moreover, some risk factors were observed to be associated with CINV in the delayed phase.
Export Options
About this article
Cite this article as:
Xu Jing , Tang Shuhui , Li Jie , Wang Wei , Wu Meihong and Zhan Xianbao *, Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1871520621999210104194038
DOI https://dx.doi.org/10.2174/1871520621999210104194038 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metastasis: Recent Discoveries and Novel Perioperative Treatment Strategies with Particular Interest in the Hemostatic Compound Desmopressin
Current Pharmaceutical Biotechnology Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Using Naïve Bayes Algorithm to Estimate the Response to Drug in Lung Cancer Patients
Combinatorial Chemistry & High Throughput Screening Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Pleiotropic Functions of Rho GTPase Signaling: A Trojan Horse or Achilles Heel for Breast Cancer Treatment?
Current Drug Targets Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Cancer Imaging Agents for Positron Emission Tomography: Beyond FDG
Current Medical Imaging Iron Oxide Nanoparticle-induced Oxidative Stress and Genotoxicity in Human Skin Epithelial and Lung Epithelial Cell Lines
Current Pharmaceutical Design Modulation of Notch Signaling as a Therapeutic Approach for Liver Cancer
Current Gene Therapy Directing Hypoxic Tumor Microenvironment and HIF to Illuminate Cancer Immunotherapy's Existing Prospects and Challenges in Drug Targets
Current Drug Targets Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue
Current Pharmaceutical Design Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Stem Cells, Self-Renewal and Cancer of the Gastric Epithelium
Current Medicinal Chemistry The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews